Motley Fool Asset Management LLC Boosts Holdings in Bristol Myers Squibb Company (NYSE:BMY)

Motley Fool Asset Management LLC grew its position in Bristol Myers Squibb Company (NYSE:BMY) by 2.2% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 94,397 shares of the biopharmaceutical company’s stock after acquiring an additional 2,046 shares during the period. Motley Fool Asset Management LLC’s holdings in Bristol Myers Squibb were worth $5,757,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of BMY. Brighton Jones LLC raised its position in shares of Bristol Myers Squibb by 33.4% in the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock worth $1,116,000 after acquiring an additional 4,935 shares during the period. Bank Pictet & Cie Europe AG acquired a new position in shares of Bristol Myers Squibb during the 4th quarter worth about $13,094,000. Townsquare Capital LLC raised its position in shares of Bristol Myers Squibb by 51.8% during the 4th quarter. Townsquare Capital LLC now owns 227,299 shares of the biopharmaceutical company’s stock worth $12,856,000 after purchasing an additional 77,605 shares during the last quarter. Sagespring Wealth Partners LLC acquired a new position in shares of Bristol Myers Squibb during the 4th quarter worth about $892,000. Finally, Advisors Capital Management LLC raised its position in shares of Bristol Myers Squibb by 12.1% during the 4th quarter. Advisors Capital Management LLC now owns 778,963 shares of the biopharmaceutical company’s stock worth $44,058,000 after purchasing an additional 83,786 shares during the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol Myers Squibb Trading Up 1.3%

Shares of Bristol Myers Squibb stock opened at $45.96 on Monday. Bristol Myers Squibb Company has a 1 year low of $42.96 and a 1 year high of $63.33. The company has a debt-to-equity ratio of 2.54, a quick ratio of 1.11 and a current ratio of 1.21. The company has a market capitalization of $93.55 billion, a P/E ratio of 18.53, a PEG ratio of 2.35 and a beta of 0.36. The company’s fifty day moving average is $47.32 and its two-hundred day moving average is $51.82.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.07 by $0.39. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The company had revenue of $12.27 billion for the quarter, compared to the consensus estimate of $11.32 billion. During the same period last year, the firm posted $2.07 EPS. Bristol Myers Squibb’s revenue for the quarter was up .6% on a year-over-year basis. Analysts forecast that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, August 1st. Shareholders of record on Thursday, July 3rd were given a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a yield of 5.4%. The ex-dividend date of this dividend was Thursday, July 3rd. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 100.00%.

Wall Street Analyst Weigh In

Several research firms recently weighed in on BMY. Daiwa America downgraded shares of Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 5th. Daiwa Capital Markets downgraded shares of Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 price target for the company. in a research report on Tuesday, August 5th. William Blair restated a “market perform” rating on shares of Bristol Myers Squibb in a research report on Friday, April 25th. Piper Sandler initiated coverage on shares of Bristol Myers Squibb in a report on Tuesday, April 22nd. They issued an “overweight” rating and a $65.00 price objective for the company. Finally, Jefferies Financial Group cut their price objective on shares of Bristol Myers Squibb from $70.00 to $68.00 and set a “buy” rating for the company in a report on Wednesday, April 23rd. One research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $56.38.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.